<tr id='ykd5h'><strong id='ykd5h'></strong><small id='ykd5h'></small><button id='ykd5h'></button><li id='ykd5h'><noscript id='ykd5h'><big id='ykd5h'></big><dt id='ykd5h'></dt></noscript></li></tr><ol id='ykd5h'><option id='ykd5h'><table id='ykd5h'><blockquote id='ykd5h'><tbody id='ykd5h'></tbody></blockquote></table></option></ol><u id='ykd5h'></u><kbd id='ykd5h'><kbd id='ykd5h'></kbd></kbd>
邁威生物宣布其首個自主商業化產品(pin)邁利舒®地舒單抗(kang)注射液獲得國(guo)家藥品(pin)監督管(guan)理局上市許(xu)可批準，正式進(jin)入(ru)國(guo)內臨床應用。該生物藥適用于骨質(zhi)疏松癥患者，具有療(liao)效(xiao)好、可及(ji)性強、國(guo)際(ji)品(pin)質(zhi)等優(you)點。(醫藥健聞)
<option id='ykd5h'></option><select id='ykd5h'><span id='ykd5h'><form id='ykd5h'></form></span><dd id='ykd5h'></dd></select><dt id='ykd5h'></dt><style id='ykd5h'><big id='ykd5h'><i id='ykd5h'></i><tbody id='ykd5h'></tbody></big></style><abbr id='ykd5h'></abbr>
